3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Breast
1
Conditions
Colorectal Neoplasms
23
Neoplasm Metastasis
14
Neoplasms
13
Rectal Neoplasms
8
Colorectal Cancer Metastatic
6
Ovarian Neoplasms
5
Lymphoma, Non-Hodgkin
5
Colonic Neoplasms
5
Uveal Melanoma
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Melanoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Fallopian Tube Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Burkitt Lymphoma
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Urethral Neoplasms
3
Stomach Neoplasms
3
Prostatic Neoplasms
3
Lung Neoplasms
3
Glioblastoma
3
Endometrial Neoplasms
3
Carcinoma, Renal Cell
3
Interventions
Gemcitabine
679
130-nm albumin-bound paclitaxel
198
Fluorouracil
186
Oxaliplatin
175
Albumin-Bound Paclitaxel
151
Capecitabine
137
Leucovorin
131
Irinotecan
113
Radiotherapy
95
Taxes
83
pembrolizumab
80
Cisplatin
72
Erlotinib Hydrochloride
69
Radiosurgery
67
Nivolumab
56
Bevacizumab
54
Drug Therapy
52
Cyclophosphamide
49
Magnetic Resonance Spectroscopy
46
folfirinox
42
Docetaxel
41
Cetuximab
40
Specimen Handling
37
irinotecan sucrosofate
36
S 1 (combination)
36
Biopsy
31
Radiation
29
Paclitaxel
29
Ipilimumab
27
durvalumab
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic Neoplasms
×
aflibercept
×
Clear all
NCT01843725
2018-01-31
MOMENTUM1
Jules Bordet Institute
Phase 1
Completed
37 enrolled
NCT00574275
2016-06-07
VANILLA
Sanofi
Phase 3
Terminated
546 enrolled
14 charts